RxDoctor Payments Data

Kristin Fisher, APRN

Nurse Practitioner · Union, MONPI 1205337441

Payments from drug & device makers

$2,471in general payments, 2019–2025

Across 105 payments — averaging $23.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$633
  • Kestra Medical Technology Services, Inc.$366
  • Boehringer Ingelheim$350
  • Novartis$246
  • W. L. Gore & Associates, Inc.$122
  • Johnson & Johnson$111
  • plus $643 from 14 others

What the payments were for

  • Food & beverage$2,471100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,471 in reported general payments places this provider in the 85th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$19,156
Medicare patients
173
Services billed
251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban196$152,798
XareltoRivaroxaban60$39,481
Repatha SureclickEvolocumab42$22,808
JardianceEmpagliflozin25$21,232
BrilintaTicagrelor35$20,656
EntrestoSacubitril/Valsartan18$13,955
Atorvastatin Calcium155$1,118
Flecainide Acetate24$1,089
ClopidogrelClopidogrel Bisulfate126$924
Metoprolol Succinate131$887
Dofetilide15$882
Bumetanide15$842
Isosorbide Mononitrate ErIsosorbide Mononitrate121$683
Potassium Chloride60$631
Diltiazem 24hr Er (Cd)Diltiazem Hcl38$593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$85$152,798196 claims
Johnson & JohnsonXarelto$111$39,48160 claims
Boehringer IngelheimJardiance$350$21,23225 claims
AstraZenecaBrilinta$57$20,65635 claims
NovartisEntresto$246$13,95518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Union

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →